Skip to content

Press Release · Press Releases

Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes

Issued by PR Newswire

Image: PR Newswire

- ASC30 reduced HbA1c by a placebo-adjusted 1.7%, 1.6% and 1.7% from baseline for 40 mg, 60 mg and 80 mg, respectively, at 12 weeks, the primary endpoint. - ASC30 achieved placebo-adjusted weight reduction of 4.4%, 3.8% and 4.0% from baseline for 40 mg, 60 mg and 80 mg, respectively and...

This press release summary is reproduced from the issuer's public feed.

Read the full release at PR Newswire

Original publisher: PR Newswire

Spotted an error? Request a correction · Corrections Policy

Related stories

Press Release

VeriSilicon présente GLTiny™, un modèle de programmation GPU 3D pour les appareils portables ultra-basse consommation et à faible consommation de mémoire

Le modèle GLTiny optimisé offre des graphismes 3D riches aux appareils portables aux ressources limitées, alimentés par des GPU OpenGL ES. SHANGHAI, 29 octobre 2026 /PRNewswire/ -- VeriSilicon (688521.SH) a annoncé GLTiny, un modèle de programmation innovant pour unités de traitement...

PR Newswire ·